Achilles Therapeutics Plc - ADR
NASDAQ:ACHL
Earnings Announcements
Achilles Therapeutics Reports First Quarter 2022 Financial Results And Recent Business Highlights
Published: 05/10/2022 11:26 GMT
Achilles Therapeutics Plc - ADR (ACHL) - Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights.
Cash Balance of $237 Million Supports All Planned Operations Into 2h 2024.
Qtrly Net Loss per Share Attributable $0.45.
Q1 Earnings per Share View $-0.51 -- Refinitiv Ibes Data (analyst estimates).
Cash Balance of $237 Million Supports All Planned Operations Into 2h 2024.
Qtrly Net Loss per Share Attributable $0.45.
Q1 Earnings per Share View $-0.51 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.56
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.62
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.56
Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.62
More details on our Analysts Page.